Terns Pharmaceuticals Reports Inducement Grant to New Employee Under Nasdaq Listing Rule 5635(C)(4)
Terns Pharmaceuticals (Nasdaq: TERN) announced the grant of equity inducement awards to a new employee under its 2022 Employment Inducement Award Plan. The company granted options to purchase 150,000 shares of common stock with an exercise price of $6.24 per share, based on the closing price on November 29, 2024. The options have a 10-year term and vest over four years, contingent on continued employment. The grant was approved by the Compensation Committee in compliance with Nasdaq Listing Rule 5635(c)(4).
Terns Pharmaceuticals (Nasdaq: TERN) ha annunciato l'assegnazione di premi azionari a un nuovo dipendente nell'ambito del suo Piano di Induzione all'Occupazione 2022. L'azienda ha concesso opzioni per l'acquisto di 150.000 azioni di azioni ordinarie con un prezzo di esercizio di 6,24 dollari per azione, basato sul prezzo di chiusura del 29 novembre 2024. Le opzioni hanno un termine di 10 anni e maturano in quattro anni, a condizione di un'occupazione continua. L'assegnazione è stata approvata dal Comitato per la Compensazione in conformità con la Regola di Listing Nasdaq 5635(c)(4).
Terns Pharmaceuticals (Nasdaq: TERN) anunció la concesión de premios en acciones a un nuevo empleado bajo su Plan de Premios de Inducción Laboral 2022. La compañía otorgó opciones para comprar 150,000 acciones de acciones ordinarias a un precio de ejercicio de 6.24 dólares por acción, basándose en el precio de cierre del 29 de noviembre de 2024. Las opciones tienen un plazo de 10 años y se devengan durante cuatro años, condicionadas a la continuidad del empleo. La concesión fue aprobada por el Comité de Compensación en cumplimiento con la Regla de Cotización del Nasdaq 5635(c)(4).
턴스 제약(Terns Pharmaceuticals) (Nasdaq: TERN)은 2022년 고용 유인 상여 계획에 따라 새로운 직원에게 주식 인센티브를 지급한다고 발표했습니다. 회사는 15만 주를 구매할 수 있는 옵션을 부여하였으며, 행사가격은 주당 6.24달러입니다. 이는 2024년 11월 29일의 종가를 기준으로 합니다. 옵션은 10년 유효 기간을 가지며, 계속 근무하는 조건 하에 4년에 걸쳐 부여됩니다. 이 발급은 Nasdaq 상장 규정 5635(c)(4)에 따라 보상위원회에서 승인되었습니다.
Terns Pharmaceuticals (Nasdaq: TERN) a annoncé l'octroi de récompenses d'incitation en actions à un nouvel employé dans le cadre de son Plan d'Attribution d'Incitation à l'Emploi 2022. La société a accordé des options d'achat de 150 000 actions ordinaires à un prix d'exercice de 6,24 $ par action, basé sur le prix de clôture du 29 novembre 2024. Les options ont une durée de 10 ans et prennent effet sur quatre ans, sous réserve d'un emploi continu. L'octroi a été approuvé par le Comité de Rémunération conformément à la Règle de Cotation Nasdaq 5635(c)(4).
Terns Pharmaceuticals (Nasdaq: TERN) gab die Gewährung von Aktieneinheiten an einen neuen Mitarbeiter im Rahmen seines 2022er Beschäftigungsanreizplans bekannt. Das Unternehmen gewährte Optionen zum Kauf von 150.000 Aktien mit einem Ausübungspreis von 6,24 US-Dollar pro Aktie, basierend auf dem Schlusskurs vom 29. November 2024. Die Optionen haben eine Laufzeit von 10 Jahren und vests über vier Jahre, abhängig von der fortgesetzten Beschäftigung. Der Zuschuss wurde vom Vergütungsausschuss gemäß der Nasdaq-Listing-Regel 5635(c)(4) genehmigt.
- None.
- None.
FOSTER CITY, Calif., Dec. 02, 2024 (GLOBE NEWSWIRE) -- Terns Pharmaceuticals, Inc. (“Terns” or the “Company”) (Nasdaq: TERN), a clinical-stage biopharmaceutical company developing a portfolio of small-molecule product candidates to address serious diseases, including oncology and obesity, today announced that it has granted as of December 1, 2024 an equity inducement award to a new employee under the terms of the 2022 Employment Inducement Award Plan, as amended (the “Inducement Plan”). The equity award was approved by the Compensation Committee of the Company’s Board of Directors in accordance with Nasdaq Listing Rule 5635(c)(4) and was made as a material inducement to the employee’s acceptance of employment with Terns.
The Company granted options to purchase 150,000 shares of Terns common stock to the new employee. The options have a 10-year term and an exercise price per share equal to
About Terns Pharmaceuticals
Terns Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company developing a portfolio of small-molecule product candidates to address serious diseases, including oncology and obesity. Terns’ pipeline contains three clinical stage development programs including an allosteric BCR-ABL inhibitor, a small-molecule GLP-1 receptor agonist, a THR-β agonist, and a preclinical GIPR modulator discovery effort, prioritizing a GIPR antagonist nomination candidate. For more information, please visit: www.ternspharma.com.
Contacts for Terns
Investors
Justin Ng
investors@ternspharma.com
Media
Jenna Urban
Berry & Company Public Relations
media@ternspharma.com
FAQ
What stock options did Terns Pharmaceuticals (TERN) grant to its new employee on December 1, 2024?
What is the exercise price for TERN's employee stock options granted on December 1, 2024?
What is the vesting schedule for TERN's December 2024 employee stock options?
